NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01817452,"A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol",https://clinicaltrials.gov/study/NCT01817452,ADAPT,COMPLETED,Trial to evaluate efficacy of dual blockade with two anti-HER2 agents with or without chemotherapy backbone within the ADAPT trial.,NO,Breast Cancer,DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Paclitaxel,"Definition of a biomarker (profile) characterizing ""good responders"" to dual blockade T and P anti-HER2 blockade that have similar pCR rates as patients treated with identical dual anti-HER2 blockade + taxane backbone, pCR will be measured after 12 weeks of randomized treatment., After 12 weeks of therapy",,,West German Study Group,Roche Pharma AG,FEMALE,"ADULT, OLDER_ADULT",PHASE2,220,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,WSG-AM06 / ADAPT HER2+/HR-,2014-03,2025-01-15,2025-01-15,2013-03-25,,2025-02-26,"Ev. Krankenhaus Bethesda Brustzentrum Niederrhien, Moenchengladbach, 41061, Germany",
